Market evolution: Nitrogen heterocyclic compounds (CN 293399) — 2015–2025

Introduction

This report examines the evolution of EU trade in heterocyclic compounds with nitrogen hetero-atom(s) only (Combined Nomenclature code 293399) over the 2015–2025 period. CN 293399 is a residual category within chapter 2933, covering a broad range of nitrogen-containing heterocyclic compounds not captured by more specific codes — including indole and its derivatives, benzotriazole phenols, and a wide variety of other structures used as pharmaceutical intermediates, agrochemicals, and specialty chemicals.

The period under review has been marked by a dramatic structural transformation in EU trade flows. The EU has shifted from being a modest net exporter in 2015 to a heavily import-dependent market by 2025, with the trade balance swinging from a surplus of €672 million to a deficit exceeding €15.3 billion. This transformation has been driven by an unprecedented surge in imports from Asia — principally China and India — even as EU production and export values have contracted. The following sections analyse the main dynamics behind this shift, the changing geography of trade, and the growing structural vulnerabilities that have emerged.

1. A tidal wave of Asian imports reshapes the EU market

Import values have surged far beyond volume growth

The most striking feature of the 2015–2025 period is the extraordinary growth in EU imports. In value terms, total EU imports rose from €2.76 billion in 2015 to €17.40 billion in 2025, an increase of 530.3%. Import volumes grew far more modestly — from 30,470 tonnes to 41,660 tonnes (+36.7%) — indicating that the value explosion was overwhelmingly driven by rising unit prices. Average import prices climbed from €90,554 per tonne in 2015 to €417,333 per tonne in 2025, a gain of 360.9%.

The near-doubling of the sub-segment CN 29339980's import price — the dominant residual category — is particularly noteworthy. Its unit price rose from €90,666/t in 2015 to €416,880/t in 2025, suggesting that the composition of imports has shifted toward higher-value, more specialised compounds over the decade.

China and India account for the overwhelming share of import growth

The import surge has been concentrated overwhelmingly in two origins. Imports from China grew from €328 million to €8.37 billion (+2,453%), while imports from India increased from €178 million to €5.94 billion (+3,230%). Together, these two countries now account for roughly €14.3 billion of the EU's €17.4 billion in total imports from non-EU countries — approximately 82% of the total.

Switzerland remains a significant import source (€2.45 billion) but its growth (+45.6%) has been far more modest, reflecting its already-established role as a specialty chemicals hub. Meanwhile, imports from Japan have nearly halved, dropping from €206 million to €105 million — consistent with the broader trend of Asian chemical production shifting to lower-cost Chinese and Indian manufacturers.

Rising import unit prices signal a shift in product mix and/or pricing power

The dramatic divergence between volume growth (+36.7%) and value growth (+530.3%) for imports warrants careful attention. For the dominant sub-line 29339980, the import unit price trajectory shows a near-continuous upward trend:

This near-quintupling of import unit prices could reflect several factors: a shift toward higher-value downstream intermediates (particularly pharmaceutical active ingredients and advanced intermediates), supply-chain inflation, or a reclassification of products within this residual code. The fact that the increase accelerated sharply from 2021 onwards — coinciding with post-pandemic demand recovery, energy cost inflation in Europe, and the growing role of Indian and Chinese CDMO (Contract Development and Manufacturing Organisation) suppliers — suggests a genuine structural shift rather than a mere statistical artefact.

2. EU exports decline in value despite resilient volumes

Export values have fallen by 40% while volumes edge up

In contrast to the import boom, EU exports have contracted significantly. Total export value fell from €3.43 billion in 2015 to €2.05 billion in 2025 (−40.2%), even as export volumes rose slightly from 15,227 tonnes to 16,701 tonnes (+9.7%). The entire decline is therefore attributable to a collapse in export unit prices, which dropped from €225,321/t to €122,713/t (−45.5%).

The divergence between falling export prices and rising import prices is a key feature of the period. EU exporters appear to have lost pricing power, possibly because they face growing competition from the very Asian producers who are simultaneously increasing their EU-bound shipments.

The United States and Japan have sharply reduced their EU sourcing

The steepest export declines have been recorded in the EU's relationships with developed-economy partners. Exports to the United States fell from €1.57 billion to €561 million (−64.2%), while exports to Japan dropped from €228 million to €74 million (−67.6%). Exports to the United Kingdom also declined sharply from €220 million to €85 million (−61.1%).

Brazil stands out as a rare growth market (+32.3%), rising from €165 million to €218 million. However, this increase is modest in absolute terms and insufficient to offset the losses elsewhere.

EU Member State export performance reveals a dramatic reshuffling

At the Member State level, the picture is one of significant redistribution. Belgium's exports collapsed from €1.93 billion to just €67 million (−96.5%), the steepest decline of any EU exporter. This may reflect the closure or restructuring of major production facilities, or the rerouting of trade flows through other EU Member States. Ireland's exports more than doubled from €387 million to €777 million (+100.8%), possibly reflecting the expansion of pharmaceutical manufacturing capacity in Ireland. Italy (+196.9%) and France (rising from virtually zero to €166 million) also showed notable growth.

Price shocks have amplified the export-side volatility

The export channel has experienced notable price shocks. In 2023, price shocks were detected for EU exports to China (unit price shift of +97.3%, abnormality score 15.1) and to Switzerland (+110.8%, abnormality score 10.1). A third shock was recorded in 2019 for exports to Japan (+60.3%, abnormality score 10.7). These episodes likely reflect changes in the product mix shipped — a shift toward higher-value compounds — rather than generalised price inflation, given that the long-term export price trend has been downward.

On the import side, the highest coefficient of variation in import values was recorded for Hong Kong (CV 1.16), Israel (CV 1.08), and the United Kingdom (CV 0.68), indicating highly volatile or sporadic trade relationships. Among the major partners, Switzerland's import CV of 0.51 and Indonesia's of 0.48 also stand out. On the export side, India (CV 0.57) and Russia (CV 0.56) showed the highest volatility among key destinations.

3. Growing import dependency and structural vulnerability

The EU has swung from trade surplus to deep deficit

The combined effect of import growth and export decline has been a fundamental transformation in the EU's net import reliance. In 2015, the EU ran a trade surplus of €672 million with non-EU countries. By 2025, this had become a deficit of €15.35 billion. Net import reliance, which was deeply negative (indicating a net exporter) at the start of the period, reached 77.6% by 2025.

EU production has contracted, reinforcing import dependency

The shift toward import dependency has been compounded by a decline in domestic production. According to PRODCOM data, EU production volume fell from 901 million kg to 484 million kg (−46.2%), while production value declined from €5.94 billion to €4.67 billion (−21.4%). The steeper decline in volume than in value suggests a shift toward higher-value product lines within domestic production, or the exit of producers manufacturing lower-value bulk compounds.

The export propensity — the ratio of exports to production — remained very high at 163.7% in 2025 (down from 168.7% in 2015), indicating that the EU continues to be a significant re-exporter and that a large share of what is imported is processed and re-exported as higher-value products. Trade intensity declined from 140.3% to 110.4%, reflecting the growing weight of the domestic market relative to trade.

Import concentration remains moderate but partner dependency is shifting

Import concentration as measured by the Herfindahl-Hirschman Index (HHI) by value declined modestly from 4,115 to 3,764 (−8.5%), indicating a slight diversification of import sources. However, this headline figure masks a concentration risk: with China and India jointly accounting for over 80% of imports by value, the effective dependency on Asian suppliers has intensified dramatically.

Notably, the volume-based import HHI actually rose from 3,010 to 3,833 (+27.3%), indicating that physical shipments have become more concentrated by origin even as values have diversified — likely because Chinese and Indian suppliers now ship larger volumes of both high- and low-priced products.

Specialisation is concentrated in a handful of Member States

Within the EU, export specialisation in CN 293399 is heavily concentrated. Ireland leads with a Revealed Symmetric Comparative Advantage (RSCA) of 0.82 and an RCA of 10.40, reflecting its dominant pharmaceutical manufacturing base. Belgium (RSCA 0.25), Italy (0.20), France (0.18), and Cyprus (0.13) follow, all with RCA values above 1 indicating some degree of comparative advantage. At the other extreme, Romania, Malta, Bulgaria, Portugal, and Croatia show negligible specialisation (RCA near zero), confirming that CN 293399 trade is concentrated in a few western European Member States.

Conclusion

The EU market for nitrogen heterocyclic compounds (CN 293399) has undergone a profound structural transformation between 2015 and 2025. The most consequential shift has been the near-severance of the traditional balance between EU production, exports, and imports: the EU has moved from being a modest net exporter to a heavily import-dependent market, with a trade deficit of over €15 billion by 2025. This has been driven primarily by an explosive increase in imports from China (+2,453%) and India (+3,230%), whose combined share of EU imports now exceeds 80%.

At the same time, EU export performance has deteriorated significantly — down 40% in value — with major losses in traditional markets such as the United States and Japan. Domestic production has also contracted sharply, particularly in volume terms (−46.2%). A few Member States, notably Ireland and Italy, have managed to expand their export positions, but these gains are insufficient to offset the broader decline.

The growing reliance on Asian suppliers, combined with the high concentration of trade flows, creates meaningful vulnerability for the EU's chemical and pharmaceutical supply chains. While import source diversification appears stable by HHI measures in value terms, the physical volume concentration has actually increased. Policymakers and industry stakeholders should monitor these trends closely, particularly as geopolitical tensions and supply-chain resilience considerations increasingly shape strategic decisions in the European chemicals sector.